论文信息 - An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer - 字舞流文

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

D. Matei | W. Figg | L. Rosen | E. Chiorean | C. Theuer | C. Peer | J. Goldman | M. Gordon | B. Seon | D. Mendelson | F. Robert | R. Strother | B. Adams | D. Alvarez